AQST: Completing to the downsideStrength is constructive, but even with only the tail end of this stock's price pattern, it appears price has reached deeply enough back to the upside to expand the upper diagonal enabling the move back down for completion in the target box.Shortby CuzDeluxPublished 0
AQST All goes well and as planned for the companyAQST all pull backs can be used as new buying opportunities. FDA Type C Meeting The Company also successfully completed a Type C meeting with the FDA that addressed open items from the November 2022 End-of-Phase 2 meeting including addressing (1) the impact of any product hold time, (2) the potential for emesis (vomiting), and (3) the impact of potential mouth conditions such as angioedema (swelling). In response to these questions, the FDA indicated that the Company has “adequately addressed” the FDA’s previous concerns by removing product hold time from the administration instructions and provided additional information on how to characterize emesis in the Company’s NDA submission. Note: Several more steps to do for Anaphylm. Focus and wait. Longby chartreader_proPublished 0
Aquestive Therapeutics Reports Positive Topline Data from Part 1AQST: Aquestive Therapeutics, Inc. 2022-02-25 07:00:00 Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Longby RocketTickersPublished 0
Aquestive Therapeutics Reports Positive Topline Data from Part 1AQST: Aquestive Therapeutics, Inc. 2022-02-25 07:00:00 Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral FilmLongby RocketTickersPublished 0
Aquestive Therapeutics Reports Positive Topline Data from Phase AQST: Aquestive Therapeutics, Inc. 2021-10-25 08:31:00 Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of AllergiLongby RocketTickersPublished 0
AQST 1WWkly falling wedge setting up for a market structure break and rest to start a 5 wave move possibly. looking for a clearance of the Dec 2, 2019 orderblock for long-term growthLongby MatrixEdgePublished 0
AQST breaking downtrendAQST has broken up from an old downtrend. PT1 - 4.69 PT2 - 5.71Longby Toro_LocoPublished 1
AQST PDUFA Approval on the SecondYou guys know I love biotechs with press releases coming up. I also like to wait to enter until the charts look bullish. Aquestive Therapeutics fell from $8 to $4 in September 2020, and I think they could pull back eventually, regardless of press releases. Now that they have an approval coming up on the second, I expect them to perform phenomenally for the rest of February. They may even push all the way back up to $8. I chose to post now because they look very bullish, at the bottom of the RSI and the MACD looks like it may cross soon. Good Luck!Longby Investor4321Published 224
Both its technical analysis and fundamental reports look great. Both its technical analysis and fundamental reports look great. This is a perfect time to buy this stock.Longby simers.coPublished 1
AQST Pattern Bullish Golfing and Line of Support The market found a line of resistance 4,60. Therefore, the market can rising next days. Longby MarcusllUpdated 115
$AQST can rise in the next daysContextual immersion trading strategy idea. Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The share price rose after good earnings. I see some preconditions the share price will continue growing. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $6,45; stop-loss — $6,00. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!Longby KozakHlibUpdated 6
Best Penny Stocks 🚀 to buy and watch in May 2020NASDAQ:AQST 😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks Our Strategy with this Stock : the company will release the drug for Parkinson disease treatment, The analysts are writing the stock at $17 to drive the sheep to buy the stock , while safe Traders will look for a high price of 6.18 $ . I'm putting two alarms, one at 4.79 to monitor any anticipatory run up. I'm putting two alarms, one at 3.37 to monitor if it hit the support . What’s the real story : The beauty of Penny stock that I trade in particular , They are ALL pharmaceutical companies. The AMAZING part is 90% of Biotech penny stocks get approved , Still there is 10% that will go the other way ! That's why I'm here for my students to scan all the markets and give them the conclusion that I personally apply . How can you actually use this ? We ONLY trade regarding the news ! Meaning that when we see the anticipatory run UP I start trading it and letting my students and followers take the advantage 👨🎓. The Best Part You can follow me and apply my trades for FREE !!! QUESTIONS ? Please comment below , what you have in mind 😊 Longby UnknownUnicorn6877177Published 3311
Aquestive Therapeutics Receives FDA Approval for Exservan™ (riluAQST: Aquestive Therapeutics, Inc. 2019-11-25 08:00:10 Aquestive Therapeutics Receives FDA Approval for Exservan™ (riluzole) Oral FilmLongby JetEquitiesPublished 3
AQSTFuture Catalyst: 11/18/2018 PDUFA date for tentative approval November 18, 2018. Market cap: 439m Float: 26.4M short float 1.16% NASDAQ:AQST Company Finance: 2.0 Debt / beat EPS, missed on Revs - recent ER Twitter sentiment positive Analyst: Positive NYSE:MNK -2.09% Shortby overwatchtraderPublished 0